stockrowVir Biotechnology, Inc.
VIRVir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
- Revenue
- −178.3%
- EPS
- +51.4%
- Free cash flow
- +36.8%
Quarter to September 2026, against a year earlier
Follow VIR
Alert me
Vir Biotechnology, Inc. (VIR) Revenue
Vir Biotechnology, Inc.'s revenue for fiscal 2025 was $68.6M, down 7.61% from $74.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $302.8M. Over the past ten years it has ranged from $2.7M (fiscal 2017) to $1.6B (fiscal 2022); the current reading is higher than 44% of that period. Revenue has fallen for 3 consecutive fiscal years. Vir Biotechnology, Inc. ranks 56th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $68.6M | (7.61%) |
| FY2024 | $74.2M | (13.90%) |
| FY2023 | $86.2M | (94.67%) |
| FY2022 | $1.6B | 47.51% |
| FY2021 | $1.1B | 1,334.39% |
| FY2020 | $76.4M | 843.86% |
| FY2019 | $8.1M | (24.16%) |
| FY2018 | $10.7M | 293.94% |
| FY2017 | $2.7M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | −$188.0K | — |
| Jun 2026 | $238.9M | — |
| Mar 2026 | −$29.0K | — |
| Dec 2025 | $64.1M | 26,595.83% |
| 28 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| VIR Vir Biotechnology, Inc. | $302.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $282.0M |
| ZYME Zymeworks Inc. compare | $266.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | $68.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| IMNM Immunome, Inc. compare | $12.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on VIR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement